Bicycle Therapeutics

Founded in 2004, Pharmaron is a cutting-edge, fully integrated pharmaceutical R&D service platform supporting the life science industry. The company has invested in its people and facilities and established its comprehensive service offerings throughout the pharmaceutical R&D lifecycle. With operations in China, the US and the UK staffed by more than 11,000 employees, Pharmaron has an excellent track record in delivering end-to-end R&D solutions to its partners globally and enabling them to accelerate their novel drug discovery and development process.

Pharmaron is a contract research organization (CRO).

Services:
* Synthetic, medicinal and analytical chemistry services
* Biology services
* DMPK services
* Pharmacology services
* Drug safety assessment services
* Radiochemistry and isotopically labelled metabolism services
* Chemical & pharmaceutical development services
* Clinical development services

www.pharmaron.com

CRO - Contract Research Organization
Library Synthesis
CADD
Bioorganic Chemistry
Discovery Process Chemistry
Radiolabelled Chemical Synthesis
ChemInformatics
in vitro Biology
in vitro Screening
Structural Biology
in vivo Pharmacology
Animal Disease Models
ex vivo Pharmacology
Biomarkers
in vitro ADME
in vivo PK
PKPD
QA
Regulatory Affairs
Discovery Biologics
Process Chemistry
API Manufacturing
Material Science
Formulation Development
Drug Product Manufacturing
Toxicology
Safety Pharmacology
Genetic Toxicology
DART
Pathology
Immunotoxicity
Bioanalytical
14C / Carbon-14 Radiosynthesis
3H / Tritium Radiosynthesis
QWBA
mARG
Clinical AME
Mass Balance
Metabolite Profiling
Microdosing Phase 0
Absolute Bioavailability
DDI
First-in-Human (FIH)
Thorough QT(TQT)
Ethnobridging

Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high-quality purified proteins and reagent solutions - notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, and cell and gene therapy workflow solutions including T-Cell activation technologies. Bio-Techne’s portfolio also includes protein analysis solutions, sold under the ProteinSimple brand name, that offer researchers efficient and streamlined options for automated Western blot and multiplexed ELISA workflow. These reagent and protein analysis solutions are sold to biomedical researchers, as well as clinical research laboratories, and constitute the Protein Sciences Segment.

Bio-Techne also develops and manufactures diagnostic products including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls, and other reagents for OEM and clinical customers. Bio-Techne’s genomic tools include advanced tissue-based in situ hybridization assays (ISH) for research and clinical use, sold under the ACD brand, as well as a portfolio of clinical molecular diagnostic oncology assays including the ExoDx®Prostate (IntelliScore) test (EPI) for prostate cancer diagnosis. These diagnostic and genomic products comprise Bio-Techne’s Diagnostics and Genomics Segment.

Bio-Techne products are integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $714 million in net sales in fiscal 2019 and has over 2,200 employees worldwide.

Immunitrack provides a product and service pipeline to optimize immunogenicity assessments during drug development, as well as a broad portfolio of reagents to monitor patient CD8 and CD4 T cell responses to lead drug candidates during early R&D and clinical trials.

How Can Immunitrack Help R&D?
The Major Histocompatibility Complex (MHC) is critical to the immune response. Immunitrack has world-leading expertise in the manufacture and application of MHC I and II molecules to accurately study MHC epitope binding through our proprietary NeoScreen® platform.

Major Areas of Application
• Immuno-oncology: selection and study of neo-epitopes for personalized cancer vaccine development
• Vaccine development: selection of immunogenic epitopes from viral and bacterial targets
• Reducing immunogenicity of biologics: reduce the risk of anti-drug antibody development by identifying and removing CD4 T cell epitopes in candidate biologics.

Reagents
We produce customized MHC tetramers to detect and quantify subsets of patient immune (T) cells with specificity towards a given antigen within blood samples.

All of our MHC I reagents are produced on our optimized manufacturing platform, and we guarantee 100% peptide loading of each complex.

Binding Assays
Our unique NeoScreen® platform combines more than a decade of world-leading expertise in MHC/epitope binding assays with a high level of automation. The result is a highly scalable and accurate platform that can screen thousands of (neo-)epitopes.

Depending on the desired immune response our clients can then select and progress the best candidates through therapeutic development. Our repository is continuously growing, and currently holds more than 70 different MHC I and 20 MHC II alleles.

ImQuest BioSciences is a preclinical contract research and development organization (CRO) that provides services to evaluate the potential of new and novel pharmaceutical products for the treatment and prevention of viruses, bacteria, cancer and inflammatory diseases.

As part of our ImQuest SUCCESS platform, we provide expert preclinical research services, including compound screening to define compound efficacy and drug target validation analysis to define the mechanism of action and toxicity of pharmaceutical products. We specialize in the development of small molecules, natural products, biologics, antimicrobial peptides, therapeutic antibodies and vaccines for infectious disease and cancer drug development programs.

Our preclinical contract research services are comprised of interrelated efficacy-defining components for infectious disease (including microbiology and virology), cancer and women's health with parallel evaluations of in vitro and ex vivo toxicity and the pharmaceutical properties and chemical structure of preclinical candidates to efficiently validate you drug target.

We are committed to earning our client's trust and building long term relationships through collaboration, unwavering commitment to quality science and consistent and effective communication. Our team has decades of experience in the field of virology, microbiology and oncology. As such, we understand that each product and each client is unique and we strive to provide effective solutions.

MBL International Corporation (MBLI) is a leading life science company focused on providing solutions for researchers in the life sciences, drug discovery and development and clinical diagnostics fields. Our special emphasis is on immunology, immuno-oncology, oncology and autoimmune disease areas. As a JSR Life Sciences Company, MBLI is committed to improve the probability of success, decrease timelines, and increase the efficacy of biologics-based therapies for the benefit of patients.

Our products are used widely in academic research and medical institutions, pharmaceutical and biotechnology companies, government agencies as well as hospital and reference laboratories. We are focused on developing high quality products and have high standards for quality control in our manufacturing process. Our products include MHC monomers and multimers, antibodies, recombinant proteins, fluorescent proteins, and ELISA kits. Our products are highly cited and support numerous research fields relating to oncology, allergy, apoptosis, autophagy, epigenetics and neuroscience.

MBLI is known for its line of immune monitoring reagents, including MHC Tetramers and Monomers, as well as our line of QuickSwitch™ products for screening peptides and neoantigens. We help researchers to acquire reliable and reproducible immune monitoring results for the areas of immuno-oncology, autoimmune, vaccine development and more.

MBLI is committed to increasing the efficiency and effectiveness of its customers’ science by delivering quality products with uncompromising support through our scientific sales, customer service, and technical support teams. Our goal is to ensure that our customers get the products and assistance when they need it.

Headquartered in Woburn, MA, with a manufacturing location in Des Plaines, IL, MBLI’s extens

Contact MBL International today to learn more about how we can help you discover ways to make your science more efficient and effective. Contact sales@mblintl.com